The market for acute pancreatitis is projected to grow significantly, reaching approximately US$ 8,827.37 million by 2030, up from US$ 5,649.77 million in 2022. This growth represents a compound annual growth rate (CAGR) of 5.7% from 2022 to 2030.
The pancreas plays a crucial role in producing insulin, a hormone essential for regulating blood glucose levels. When pancreatitis occurs, it can damage the insulin-producing cells within the pancreas, leading to diabetes in individuals affected by acute pancreatitis. Those with acute pancreatitis face a doubled risk of developing diabetes compared to the general population. The World Health Organization (WHO) and the American Diabetes Association have identified diabetes that develops following acute pancreatitis as exocrine pancreatic diabetes, also known as pancreatogenic diabetes. This condition is increasingly associated with disorders affecting the exocrine function of the pancreas. The complications of diabetes can manifest across various severity levels in acute pancreatitis and may coincide with other clinical issues.
According to a 2022 publication in the European Review for Medical and Pharmacological Sciences, the prevalence of pancreatogenic diabetes among the Western diabetic population ranges from 5% to 10%. Chronic pancreatitis accounts for 20% of these cases, while acute pancreatitis is responsible for 80%. An article from the National Library of Medicine in 2021 indicates that approximately 23% of patients who experience acute pancreatitis are likely to develop diabetes within three years post-discharge. Furthermore, research published in the Journal of Gastroenterology in 2020 reveals that around 3%, 7%, 9%, and 11% of patients develop diabetes at 6, 12, 18, and 24 months after discharge, respectively. A 2023 study in MDPI highlights that nearly 40% of individuals with acute pancreatitis are affected by prediabetes or diabetes, facing a higher risk of mortality and hospital readmission compared to those with type 2 diabetes. Additionally, about 60.2% of adult patients develop diabetes following acute pancreatitis, while 9% of children with acute recurrent pancreatitis or chronic pancreatitis are also at risk, with the likelihood increasing as they transition into adulthood. A meta-analysis has shown that the incidence of diabetes is significantly higher (~39%) after severe acute pancreatitis compared to mild cases (14%).
Research from China indicates that hypertriglyceridemia (HTG) has surpassed alcohol as the second leading cause of acute pancreatitis. Approximately 29% of patients experience recurrent episodes, leading to recurrent acute pancreatitis (RAP), with 44.6% of these cases attributed to HTG. An article published in Biomed Central in June 2023 identifies HTG as a significant independent risk factor for both the severity and recurrence of acute pancreatitis. Consequently, the rising incidence of diabetes among patients with acute pancreatitis is a contributing factor to the expansion of the acute pancreatitis market.
The acute pancreatitis market is categorized by product type and end user. In terms of offerings, the market is divided into medication, diagnostic tools, and other categories. In 2022, the diagnostic segment held the largest market share, and the other segment is anticipated to exhibit the fastest CAGR during the forecast period from 2022 to 2030. The diagnostic segment itself is further divided into blood tests, CT scans, stool tests, ultrasounds, MRIs, and urine tests. Regarding causative factors, the market is classified into gallstones, alcohol consumption, genetic disorders, infections, and other causes. In 2022, gallstones represented the largest market share and are expected to show the highest CAGR during the forecast period. The end-user classification includes hospitals, diagnostic laboratories, ambulatory surgical centers, and others, with hospitals holding the largest market share in 2022. The diagnostic laboratories segment is projected to grow at a CAGR of 6.4% during the forecast period.
Geographically, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America currently holds the largest share of the acute pancreatitis market, driven by the increasing prevalence of the disease, particularly due to rising gallstone cases and high alcohol consumption rates. Technological advancements in healthcare facilities are also contributing positively to the market in this region. The United States, in particular, reports a significant number of acute pancreatitis cases linked to widespread alcohol use and a rise in gallstone occurrences. The Asia Pacific region is expected to experience the highest growth rate from 2022 to 2030, attributed to the increasing incidence of pancreatitis, ongoing research for treatment options, and government initiatives aimed at raising public awareness. Additionally, cases of alcohol-related pancreatitis are further propelling market growth in this area.
Key sources referenced in the report on the acute pancreatitis market include the Organisation for Economic Co-operation and Development (OECD), the Centers for Disease Control and Prevention (CDC), the European Union, and the National Institutes of Health (NIH).